Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gut microbiome and immune checkpoint inhibitor toxicity.
Verheijden RJ, van Eijs MJM, Paganelli FL, Viveen MC, Rogers MRC, Top J, May AM, van de Wijgert JHHM, Suijkerbuijk KPM; UNICIT-consortium. Verheijden RJ, et al. Among authors: suijkerbuijk kpm. Eur J Cancer. 2025 Jan 4;216:115221. doi: 10.1016/j.ejca.2025.115221. Online ahead of print. Eur J Cancer. 2025. PMID: 39793444 Free article.
Frailty and checkpoint inhibitor toxicity in older patients with melanoma.
Bruijnen CP, Koldenhof JJ, Verheijden RJ, van den Bos F, Emmelot-Vonk MH, Witteveen PO, Suijkerbuijk KPM. Bruijnen CP, et al. Among authors: suijkerbuijk kpm. Cancer. 2022 Jul 15;128(14):2746-2752. doi: 10.1002/cncr.34230. Epub 2022 Apr 19. Cancer. 2022. PMID: 35439334 Free PMC article.
Physical activity and checkpoint inhibition: association with toxicity and survival.
Verheijden RJ, Cabané Ballester A, Smit KC, van Eijs MJM, Bruijnen CP, van Lindert ASR, Suijkerbuijk KPM, May AM. Verheijden RJ, et al. Among authors: suijkerbuijk kpm. J Natl Cancer Inst. 2024 Apr 5;116(4):573-579. doi: 10.1093/jnci/djad245. J Natl Cancer Inst. 2024. PMID: 38001030 Free PMC article.
Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.
Verheijden RJ, Burgers FH, Janssen JC, Putker AE, Veenstra SPGR, Hospers GAP, Aarts MJB, Hehenkamp KW, Doornebosch VLE, Verhaert M, van den Berkmortel FWPJ, Chatzidionysiou K, Llobell A, Barros M, Maria ATJ, Takeji A, García Morillo JS, Lidar M, van Eijs MJM, Blank CU, Aspeslagh S, Piersma D, Kapiteijn E, Labots M, Boers-Sonderen MJ, van der Veldt AAM, Haanen JBAG, May AM, Suijkerbuijk KPM. Verheijden RJ, et al. Among authors: suijkerbuijk kpm. Eur J Cancer. 2024 Aug;207:114172. doi: 10.1016/j.ejca.2024.114172. Epub 2024 Jun 15. Eur J Cancer. 2024. PMID: 38905818 Free article.
Lower risk of severe checkpoint inhibitor toxicity in more advanced disease.
Verheijden RJ, May AM, Blank CU, van der Veldt AAM, Boers-Sonderen MJ, Aarts MJB, van den Berkmortel FWPJ, van den Eertwegh AJM, de Groot JWB, van der Hoeven JJM, Hospers GAP, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, van Zeijl MCT, Wouters MWJM, Haanen JBAG, Kapiteijn E, Suijkerbuijk KPM. Verheijden RJ, et al. Among authors: suijkerbuijk kpm. ESMO Open. 2020 Nov;5(6):e000945. doi: 10.1136/esmoopen-2020-000945. ESMO Open. 2020. PMID: 33199288 Free PMC article.
144 results